Who owns AXGT - AXOVANT GENE THERAPIES LTD - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

AXOVANT GENE THERAPIES LTD - COM (AXGT) Institutional Ownership

Q: What is CUSIP G0750W203?

CUSIP G0750W203 is the security identifier used in SEC filing datasets for AXGT - AXOVANT GENE THERAPIES LTD - COM.

CUSIP: G0750W203

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2020

Type / Class: Equity / COM
Symbol: AXGT

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP G0750W203?
CUSIP G0750W203 identifies AXGT - AXOVANT GENE THERAPIES LTD - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP G0750W203:

Q4 2020 (0 holders) Q3 2020 (39 holders) Q2 2020 (32 holders) Q1 2020 (35 holders) Q4 2019 (37 holders) Q3 2019 (37 holders) Q2 2019 (32 holders) Q1 2019 (2 holders)

Institutional Holders of AXOVANT GENE THERAPIES LTD - COM (AXGT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2020 Q4	0	$0	-$52,736,626	$0	$0		0
2020 Q3	11,414,563	$52,736,631	-$1,928,174	$1,438,000	$917,000	$4.62	39
2020 Q2	11,936,862	$33,658,003	+$976,428	$387,000	$231,000	$2.82	32
2020 Q1	11,627,293	$28,371,027	+$21,456,381	$302,000	$246,000	$2.44	35
2019 Q4	2,611,986	$13,373,056	-$5,224,498	$1,351,000	$3,599,000	$5.12	37
2019 Q3	3,372,861	$21,784,497	+$1,988,656	$1,814,000	$2,927,000	$6.46	37
2019 Q2	3,069,757	$19,124,480	+$18,720,995	$2,241,000	$2,271,000	$6.23	32
2019 Q1	216,596	$288,000	+$288,005			$1.35	2